Flamel Technologies is a specialty pharmaceutical company with a long history of expertise in drug delivery, focusing on the development of safer and more efficacious formulations, tackling unmet medical needs in the process.

Technology Platforms

  • Medusa

    Controlled release of injected biologics and small molecules drugs.

    Read more

  • LiquiTime®

    Controlled release oral liquid drugs.

    Read more

  • Micropump®

    Controlled release of oral drugs.

    Read more

  • Trigger Lock

    Tamper-resistant controlled release formulations of narcotics and other drugs prone to abuse.

    Read more


Flamel Technologies currently markets Bloxiverz (a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery) in the USA and has nine more proprietary products in its pipeline.


As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.